Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.96 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.61 |
| ▸ | HTR3B | O95264 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylphenylpiperazinium SCHEMBL1427906 | 0.98 | CHRNA7 (0.96) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| Dimethylphenylpiperazinium SCHEMBL6829257 | 0.98 | CHRNA7 (0.96) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| Dimethylphenylpiperazinium SCHEMBL305083 | 0.98 | MEN1 (1.00) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL10114942 | 0.92 | CHRNA7 (0.85) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| Iodide SCHEMBL404487 | 0.90 | MEN1 (0.85) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL10105152 | 0.81 | CHRNA7 (0.72) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL6743986 | 0.78 | ALOX15 (0.64) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL10105155 | 0.78 | CHRNA7 (0.63) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL576454 | 0.77 | LMNA (0.67) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 | |
| SCHEMBL164538 | 0.77 | LMNA (0.67) | CHRNA7CYP3A4ALOX15CHRNB2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1610714-A | Polycarbonate-siloxane copolymers | GEN ELECTRIC (US) | 2005-04-27 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0831772-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0615855-B1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORP (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996040054-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20250221923-A1 | BOOSTING OSMOTIC BLOOD-ORGAN BARRIER OPENING FOR IMPROVED DELIVERY OF THERAPEUTICS TO ORGANS | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-07-10 | — | — | US | disclosed |
| US-20240359168-A1 | Mesoporous Catalyst Compounds and Uses Thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-12064752-B2 | Mesoporous catalyst compounds and uses thereof | ExxonMobil Technology and Engineering Company (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240009269-A1 | MEMBRANE-ACTIVE PEPTIDES AND METHODS FOR REVERSIBLE BLOOD- BRAIN BARRIER OPENING | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-01-11 | — | — | US | disclosed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11733608-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11720018-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-4306085-A | Hydroformylation process using resin-ligand-metal catalyst | SHELL OIL COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| EP-0005569-B1 | RESIN-LIGAND-TRANSITION METAL COMPLEX COMPOSITION AND PROCESSES FOR USING THIS COMPOSITION AS CATALYST | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-11-04 | — | — | EP | disclosed |
| EP-0002557-B1 | RESIN-LIGAND TRANSITION METAL COMPLEX COMPOSITION AND PROCESSES FOR USING THIS COMPOSITION AS CATALYST | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-09-23 | — | — | EP | disclosed |
| US-4284835-A | METAL COMPLEX CATALYST BOUND TO RESIN | SHELL OIL COMPANY (US) | 1981-08-18 | — | — | US | disclosed |
| US-4266085-A | Olefin disproportionation process | SHELL OIL COMPANY (US) | 1981-05-05 | — | — | US | disclosed |
| US-4179402-A | Resin-metal-ligand composition | SHELL OIL COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4179403-A | Resin-ligand-metal complex compositions | SHELL OIL COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11733608-B2 | Resist composition and patterning process | HNRNPU, INSR, BICRA | CHRNA7 2834/4885CYP3A4 4628/4885ALOX15 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.